Results 121 to 130 of about 118,583,499 (297)
Therapeutics and Clinical Risk Management, 2020 Silvia Linari, Giancarlo Castaman Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, ItalyCorrespondence: Giancarlo CastamanDepartment of Oncology, Center for Bleeding Disorders and Coagulation ...
Linari S, Castaman G
doaj
Hematology, 2006 Acquired hemophilia A is a rare but severe autoimmune bleeding disorder, resulting from the presence of autoantibodies directed against clotting factor VIII. The etiology of the disorder remains obscure, although approximately half of all cases are associated with other underlying conditions.
openaire +2 more sources
The Burden of Prior Authorizations in Bleeding Disorder Specialty Drugs
Haemophilia, EarlyView.ABSTRACT Introduction Prior authorizations (PAs) are widely used to control healthcare costs and ensure appropriate use of high‐cost therapies, but they often create undue administrative burdens. In haemophilia care, timely access to specialty medications is critical, yet Haemophilia Treatment Centres (HTCs) must frequently navigate payer‐driven PA ...
Lisa Littner +3 more
wiley +1 more source
Identification of people with acquired hemophilia in a large electronic health record database
, 2017 Michael Wang,1 Anissa Cyhaniuk,2 David L Cooper,3 Neeraj N Iyer3 1Hemophilia and Thrombosis Center, University of Colorado School of Medicine, Aurora, CO, 2AC Analytic Solutions, Barrington, IL, 3Clinical Development, Medical and Regulatory Affairs, Novo
Wang M, Iyer NN, Cyhaniuk A, Cooper DL
core
Haemophilia, EarlyView.ABSTRACT Introduction Understanding patients’ and caregivers’ experiences, values and needs is essential to implement patient‐centred care. However, specific insights into how young children with haemophilia and their caregivers experience the entire care trajectory, from diagnosis onwards, remain limited.
Caroline M. A. Mussert +11 more
wiley +1 more source
Barriers and perceived limitations to early treatment of hemophilia
, 2013 Kapil Saxena Boston Hemophilia Center, Boston Children’s Hospital, Boston, MA, USA Abstract: Early treatment of bleeds in hemophilia patients, both with and without inhibitors, has been shown to be of immense benefit in the overall clinical outcome.
Saxena K
core
, 2012 Shinsaku Imashuku,1 Naoko Kudo,1 Kagekatsu Kubo,1 Katsuyasu Saigo,1 Nanako Okuno,2 Kaoru Tohyama21Division of Hematology, Takasago-seibu Hospital, Takasago, Japan; 2Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, JapanBackground ...
Tohyama K +5 more
core
Population‐Level Real‐World Healthcare Costs in Men and Women With Haemophilia A
Haemophilia, EarlyView.ABSTRACT Introduction Even with modern prophylaxis options, people living with haemophilia have significantly lower quality of life and joint health outcomes than those without. Aim Our goal was to determine if real‐world health‐system costs are higher for people living with haemophilia A compared to those without and determine how joint‐health state ...
Sam Hirniak +6 more
wiley +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Individuals diagnosed with types 1/1C/2A/2M von Willebrand disease (VWD) typically undergo a desmopressin (DDAVP) challenge to assess therapeutic benefit. This involves measuring von Willebrand factor antigen (VWF:Ag), activity (VWF:Act; VWF:RCo/VWF:GPIbM/VWF:Ab), and coagulant factor VIII (FVIII:C) levels 0 (pre), 1, and 4‐h post‐
Michael Shu +7 more
wiley +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Accurate laboratory diagnosis is essential for the effective management of bleeding disorders. The World Federation of Hemophilia (WFH) International External Quality Assessment Scheme (IEQAS) provides an international platform for comparative evaluation of laboratory performance.
Silmara de Lima Montalvão +8 more
wiley +1 more source